At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 154 enrolled
Drug / intervention
Allergovit 6-grasses +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Placebo Controlled, Double-Blind Study for Evaluation of Safety and Efficacy of Preseasonal Specific Immunotherapy With an Allergoid Preparation of an Extract of a 6 Grass Pollen Mixture in Patients With Clinically Relevant Grass Pollen Sensitivity
In Brief
A Phase 3 clinical trial evaluating Allergovit 6-grasses and Placebo for Grass Pollen Allergy. Completed, enrolled 154 participants across 1 site.
Detailed Summary
The trial is performed to assess efficacy and safety of the Grass Pollen Allergoid in Allergic Rhinoconjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrass Pollen Allergy
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2001
Primary CompletionMay 2004
First PostedDec 2005
Study CompletionAug 2010
TodayJul 2026
First PostedDec 9, 2005
Enrollment StartNov 1, 2001
Primary CompletionMay 1, 2004
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.6 years ago
Interventions
Allergovit 6-grassesbiological
Subcutaneous injections
Placeboother
Subcutaneous injections